Archive for 2012
Fibrocell Science, Inc. to Initiate Phase II Clinical Trial for Restrictive Burn Scars
Fibrocell Science, Inc., a biotechnology company at the forefront of research into the potential medical and aesthetic use of fibroblasts, plans to initiate a Phase II clinical trial to assess the potential of azficel-T for treating restrictive burn scars in first quarter, 2013. Fibroblasts are skin cells responsible for the production of collagen that contributeRead more
Fibrocell Science, Inc. Inducted into Prestigious World Technology Network
Fibrocell Science, Inc., an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, has been inducted into the distinguished World Technology Network (WTN) as a result of being named a finalist for the 2012 World Technology Award for Biotechnology. Comprised of more than 1,000 members leading innovativeRead more
Fibrocell Science, Inc. Receives Gold Award for LAVIV™ from Prestigious 2012 Golden Bridge Awards Program
Fibrocell Science, Inc. announced LAVIV® (azficel-T) received the prestigious Gold Award in the “Lifestyle, Beauty and Fashions” Innovations category at the 4th Annual 2012 Golden Bridge Awards program. According to the San Francisco based organization, honorees are selected from an array of categories ranging from individuals to Gadget Innovations, such as the iPad which alsoRead more
Fibrocell Science, Inc.’s LAVIV® Recognized in the Prestigious Wall Street Journal Technology Innovation Awards
Fibrocell Science, Inc. announced that LAVIV® (azficel-T) was recognized in this year’s Wall Street Journal Technology Innovation Awards. LAVIV, the first and only personalized cell treatment approved by the FDA to improve the appearance of nasolabial folds or “smile line” wrinkles, was named a runner-up in the Medicine and Biotech category. The Awards recognize companiesRead more
Fibrocell Science, Inc. to Host Investor Conference Call to Discuss Business Update
Fibrocell Science, Inc., a biotechnology company focused on commercializing LAVIV®, the first and only FDA-approved personalized cell therapy in aesthetic dermatology, and on developing innovative autologous cell therapies for additional aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s privateRead more
Fibrocell Science, Inc. Announces $45 Million Private Placement and Enters Strategic Collaboration with Intrexon
– Proceeds to Support Commercial Launch of LAVIV and Expand Development of their Proprietary Fibroblast Platform – – Strategic Collaboration with Intrexon to Advance Development and Commercialization of Next Generation Fibroblast Platform Programs – Fibrocell Science, Inc. (FCSC), a biotechnology company focused on commercializing LAVIV®, the first and only FDA-approved personalized cell therapy inRead more
Fibrocell Science, Inc. Announces Annual General Meeting
August 13, 2012, EXTON, PA – Fibrocell Science, Inc., today announced a reminder that its annual general meeting and corporate update will be on September 13, 2012 at 10:00 a.m. eastern. The meeting will held at the Fibrocell Science headquarters, 405 Eagleview Boulevard, Exton, Pa, 19341. Mr. David Pernock, CEO and Chairman of Fibrocell Science,Read more
Fibrocell Science, Inc. Announces Updated Investor Presentation
August 9, 2012, EXTON, PA – Fibrocell Science, Inc., has posted an updated investor presentation including updates on the pipeline, plans for expansion of manufacturing capacity and plans to reduce the cost of goods. The presentation can be accessed at fibrocellscience.com. About Fibrocell Science, Inc. Fibrocell Science, Inc. (OTCBB:FCSC.OB) is an autologous cellular therapeuticRead more
Fibrocell Science, Inc. Announces Second Quarter 2012 LAVIV Order Information
July 16, 2012, EXTON, PA — Fibrocell Science, Inc. , announced today its LAVIV order information for the second quarter ended June 30, 2012. During the second quarter of 2012, Fibrocell received orders for 387 biopsies, an increase of 104% as compared to 189 orders during the first quarter of 2012. During the second quarterRead more
Fibrocell Science, Inc. Completes $9.1 Million Capital Raise
Fibrocell Science, Inc. announced today that it has completed a private placement originally commenced in May 2012 pursuant to which it raised an aggregate of $9.1 million through the issuance of preferred stock and warrants. John Carris Investments LLC and John Thomas Financial, Inc. acted as co-placement agents for the transaction. For complete details on theRead more